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Summary This study was designed to investigate whether chronic angiotensin II
type 1 receptor blockade inhibits ventricular interstitial ﬁbrosis with the induction
of programmed cell death (apoptosis) in prolonged nitric oxide synthase (NOS) inhi-
bition using NG-nitro-L-arginine methyl ester (L-NAME) in spontaneously hypertensive
rats (SHR). Four groups of 20-week-old male SHR were studied for 3 weeks: the con-
trol group; the L-NAME group given 80mg/L L-NAME in drinking water; and the groups
given 1 or 30mg/(kg day) of valsartan, respectively, with L-NAME. The L-NAME group
showed marked cardiac tissue injuries with elevated blood pressure such as intersti-
tial ﬁbrosis, intimal thickening of small arteries, and myocardial necrosis. Caspase-3,
an apoptosis inducer, immunoreactivity was increased in interstitial cells, and the
tissue RNA expression of transforming growth factor-1 (TGF-1) was also increased
in the L-NAME group. Low-dose valsartan treatment did not affect blood pressure or
cardiac weight but alleviated the L-NAME-induced interstitial ﬁbrosis with increased
mRNA level of caspase-3 in interstitial ﬁbroblasts. High-dose valsartan signiﬁcantly
lowered blood pressure and decreased the mRNA levels of caspase-3 and TGF-1.
These data suggest that low-dose valsartan inhibits interstitial ﬁbrosis by promoting
apoptosis of the ﬁbroblasts without blood pressure changes, which may provide the
TGF-1 inhibition in the development of interstitial ﬁbrosis in severe hypertension
rat model.
© 2008 Japanese College o
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ntroductionissue angiotensin II (Ang II) plays an important
ole in the development of hypertensive cardio-
ascular organ injury. A number of studies have


















































demonstrated that inhibitors of the renin—
angiotensin—aldosterone system (RAAS) such as
angiotensin-converting enzyme (ACE) inhibitors
and angiotensin II type 1 receptor blockers (ARBs)
are effective in protecting the cardiovascular sys-
tem from hypertensive injuries by inhibiting tissue
Ang II [1,2]. In spontaneously hypertensive rats
(SHR) given NG-nitro-L-arginine methyl ester (L-
NAME), an inhibitor of nitric oxide synthase (NOS),
we have observed the development of marked
hypertensive organ injuries such as arteriosclero-
sis, nephrosclerosis, and cardiac remodeling with
the enhancement of RAAS [3—5]. We have previ-
ously demonstrated the protective effects of ACE
inhibitors and ARBs against nephrosclerosis [6,7].
Therefore, it seems intriguing to evaluate the
therapeutic effects of ARBs on the development of
cardiac remodeling in SHR given L-NAME.
In the progression of hypertensive cardiac
remodeling, occurrence of interstitial ﬁbrosis and
disappearance of cells by apoptosis are also the
indispensable process in addition to the prolifera-
tion and hypertrophy of cardiovascular cells [8,9].
Components of RAAS in the cardiovascular tissue
such as Ang II and aldosterone induce transform-
ing growth factor 1 (TGF-1). TGF-1 is produced
in cells such as cardiocytes, vascular smooth mus-
cle cells, and ﬁbroblasts and promotes ﬁbrosis of
cardiovascular tissues [10,11]. With regard to the
apoptosis of cardiovascular cells, the chain reac-
tion of the members of caspase protease family
leads cells to develop apoptosis [12]. Especially, the
role of caspase-3 is considered to be pivotal in the
cascade to cellular apoptosis [13].
In this study, we examined the effects of val-
sartan, an ARB, on the tissue remodeling of left
ventricle in SHR given L-NAME and assessed the
involvement of cardiac expression of TGF-1 and
caspase-3 in its therapeutic effects.
Methods
Forty-six 17-week-old male SHR (Charles River Lab-
oratories, Tokyo, Japan) were maintained in a light
controlled room at room temperature. All exper-
iments have been approved by our institutional
animal care committee. The rats were divided
into 4 experimental groups: group 1 rats (control,
n = 13) were given tap water and a regular chow
containing 0.3% NaCl for 3 weeks; group 2 rats (L-
NAME, n = 9) were given L-NAME (Sigma Chemical
Co., St. Louis, MO, USA) in their drinking water
(50mg/L) for 3 weeks; group 3 rats (L-VAL, n = 12)
were administered the same dose of L-NAME and
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roup 4 rats (H-VAL, n = 12) were administered the
ame dose of L-NAME and valsartan (30mg/(kg day)
y gavage) for 3 weeks. Systolic blood pressure
as measured by the tail-cuff method (Apollo 179,
sis, Osaka, Japan). After 3 weeks, the rats were
illed under pentobarbital anesthesia (30mg/kg,
.p.). The heart was perfused and ﬁxed with saline
nd neutral-buffered 8% paraformaldehyde solu-
ion. Then, the left cardiac ventricle was excised
nd weighed.
The left ventricle was embedded in parafﬁn, and
-m horizontal sections were cut for light micro-
copic histological examination. These sections
ere stained with hematoxylin—eosin, periodic
cid-Schiff (PAS), and Masson trichrome. Histo-
ogical examination was conducted in a blinded
anner. Fibrosis of the left ventricular wall
as evaluated in sections stained with Masson
richrome. The area stained in blue with aniline
as quantiﬁed in 10 randomly selected high-power
elds (200×) using a computer system (Image
uest, Hamamatsu Photonics; Hamamatsu and Mac-
cope, Mitani Co., Fukui, Japan), and the average
ercent value was used for comparison. Five-
m sections were prepared for immunohistological
tudies. After deparaﬁnization, immunostaining
f caspase-3 was carried out using the spe-
iﬁc mouse monoclonal antibody (Immunotech,
arseille, France) at dilution of 1:1000 and
he streptavidin/biotin immunoperoxidase method
LSAB kit, DAKO Japan, Tokyo, Japan). The per-
entage of the stained area in the interstitium was
uantiﬁed using the image analysis computer sys-
em. The sections were also stained by terminal
eoxynucleotidil transferase-mediated dUTP nick
nd labeling (TUNEL) method using ApoRag Per-
xidase In Situ Apoptosis Detection Kit (Intergen
ompany, New York, NY, USA) to detect apoptotic
uclei with internucleosomal DNA fragmentation.
The total RNA of specimens was extracted from
he left ventricular tissue using TRIzol reagent
Life Technologies, Rockville, MD, USA) according
o the manufacturer’s procedure. The ﬁrst-strand
DNA was made from the total RNA using the
uperScript preampliﬁcation system (Life Technolo-
ies) with random hexamers. Excess oligomers were
emoved using a centrifugal ﬁlter, Microcon YM-10
Millipore Co., Bedford, MA, USA). Real-time PCR
nalysis, using the ABI Prism 7700 Sequence Detec-
ion System (PE Biosystems, Foster City, CA, USA),
s a method that provides reproducible quantita-
ive PCR [14]. Cleavage of the sequence-speciﬁc
robe (TaqMan Probe) by 5′ nuclease activity of
he TaqDNA polymerase releases the reporter dye,
esulting in an increase in emission at the cor-




















































































Dalsartan inhibits hypertensive cardiac ﬁbrosis
uorescence intensity of additional reporter dye
olecules is monitored by the system. Threshold
ycles were selected in the line in which all sam-
les were in logarithmic phase. The quantity of PCR
roducts was calculated from the threshold cycle
alue. This real-time detection generates quanti-
ative data based on PCR at early cycles when PCR
delity is highest. TGF-1 and caspase-3 RNA levels
ere quantiﬁed as the ratios to -actin using this
eal-time PCR system. All oligonucleotides were
btained by chemical synthesis using the PerSep-
ive 8900 (PE Biosystems). TaqMan probe which
as modiﬁed with ﬂuorescence (purchased from
rener Japan, Inc., Tokyo, Japan). The nucleotide
equences of the PCR primers and TaqMan probes
ere as follows:
TGF-1
o forward primer: 5′-cgcctgcagagattcaagtcaa-3′
o reverse primer: 5′-gtcggttcatgtcatggatggt-3′
o TaqMan probe: 5′-agtggctgaaccaaggagacggaat-
aca-3′
Caspase-3
o forward primer: 5′-gtgaagaaattatggaattgatg-3′
o reverse primer: 5′-gtagtcgcctgtgaagaaactag-3′
o TaqMan probe: 5′-gattctaagtcatggagatgaaggag
-3′
-actin
o forward primer: 5′-cgtgaaaagatgacccagatca-3′
o reverse primer: 5′-acacagcctggatggctacgta-3′
o TaqMan probe: 5′-tttgagaccttcaacaccccagcca-
3′
One-way ANOVA, followed by Duncan’s multiple
ange test [15], was performed to test for between-
roup signiﬁcance. All data are expressed as the
ean± S.E.M. A probability level of <5% was con-
idered to indicate statistical signiﬁcance.
esults
able 1 lists the data of measured variables in the
our groups of rats at the end of the 3-week treat-
ent period in this study. As we have previously
eported [3—7], the L-NAME group showed blunted
ody weight increase as compared with the control
roup. The low-dose and the high-dose valsartan
revented this body weight reduction in SHR given
-NAME. The L-NAME treatment accelerated the
evelopment of hypertension in SHR. The high-dose
alsartan alleviated this blood pressure increase in
HR given L-NAME, while the low-dose valsartan did
ot signiﬁcantly affect blood pressure as compared
ith the L-NAME group. The left ventricular weight
as not signiﬁcantly different between the control






ose valsartan did not signiﬁcantly change the left
entricular weight of SHR given L-NAME.
The left panel of Fig. 1 compares the per-
entage of ﬁbrosis area in the left ventricle. As
ompared with the control group, the L-NAME
roup showed markedly increased ﬁbrosis area in
he left ventricle. The treatment with valsartan
educed this cardiac ﬁbrosis induced by L-NAME in
dose-dependent manner. Fig. 2 shows the rep-
esentative micrographs of left ventricular tissue
ections stained with Masson trichrome in each
roup. The right panel of Fig. 1 presents the
ercentage of interstitial area stained with anti-
aspase-3 antibody. The caspase-3 immunostaining
rea was signiﬁcantly increased in the L-NAME group
s compared with the control group. The caspase-
positive area was further increased in the L-VAL
nd the H-VAL groups. Fig. 3 shows the represen-
ative micrographs of caspase-3 immunostaining in
he four groups. In the L-VAL and the H-VAL groups,
nterstitial ﬁbrocytes were positively stained with
nti-caspase-3 antibody.
The left panel of Fig. 4 shows the mRNA expres-
ion of caspase-3 in the left ventricular tissue.
n accordance with the results of immunohisto-
ogical study, the caspase-3 mRNA expression was
igher in the L-NAME group and further higher in
he L-VAL and the H-VAL groups than in the con-
rol group. As shown in the right panel of Fig. 2,
he mRNA expression of TGF-1 in the left ventric-
lar tissue was signiﬁcantly increased in the L-NAME
roup as compared with the control group. Although
ow-dose valsartan did not signiﬁcantly affect this
ncreased TGF-1 mRNA in SHR given L-NAME, high-
ose valsartan treatment markedly reduced the left
entricular TGF-1 mRNA expression to the level
omparable to the control group.
Fig. 5 shows the percentage of TUNEL-positive
uclei in the ﬁbrotic area of left ventricular tis-
ue. The TUNEL-positive nuclei were signiﬁcantly
ncreased in the L-NAME group as compared with
he control group. The percentage was further
ncreased in the L-VAL and the H-VAL groups. Fig. 6
resents the representative micrographs of left
entricular tissue sections of TUNEL staining. The
uclei of perivascular ﬁbrocytes were positively
tained by the TUNEL method.
iscussionypertension is a major risk factor for cardiovas-
ular organ injuries. In addition, cardiovascular
isk factors such as aging, dyslipidemia, and dia-
etes mellitus cause endothelial dysfunction and
ecreased NO production which further promote
242 A. Akashiba et al.
Table 1 Body weight, blood pressure, and cardiac weight of rats at the end of 3-week treatment period
Indices Control (n = 13) L-NAME (n = 9) L-Val (n = 12) H-Val (n = 12)
Body weight (g) 358 ± 5 262 ± 13** 325 ± 7†† 327 ± 5††
Systolic blood pressure (mmHg) 227 ± 5 276 ± 11** 265 ± 7 242 ± 5†
Left ventricular weight (g/kg) 3.25 ± 0.18 3.52 ± 0.21 3.28 ± 0.16 3.53 ± 0.19





vFigure 1 Effects of L-NAME and valsartan treatment on i
(right panel) in left ventricular tissue. **p < 0.01 vs. contr
cardiovascular tissue injuries. In this context, SHR
given L-NAME, a NOS inhibitor, is assumed to be
a model of cardiovascular target organ injuries
caused by multiple risk factors such as hyperten-
sion and aging. In the present study, marked ﬁbrosis





Figure 2 Representative micrographs of left ventricular tissu
(A), L-NAME (B), L-VAL (C), and H-VAL (D) groups.stitial ﬁbrosis (left panel) and caspase-3 immunostaining
†p < 0.01 vs. L-NAME.
s compared with the control SHR although the left
entricular weight was not signiﬁcantly affected.
he treatment with valsartan alleviated this car-
iac ﬁbrosis in a dose-dependent manner. In rats
reated with high-dose valsartan, increased apopto-
is of ﬁbrocytes induced by caspase-3 and reduced
e sections stained with Masson trichrome in the control


































†igure 3 Representative micrographs of caspase-3 imm
-VAL (D) groups.
xpression of TGF-1, in addition to blood pres-
ure reduction, are thought to contribute to the
nhibition of cardiac ﬁbrosis. Signiﬁcant improve-
ent of cardiac ﬁbrosis was also observed in rats
reated with low-dose valsartan which did not lower
lood pressure. The low-dose valsartan did not sig-
iﬁcantly reduce TGF-1 expression but induced
aspase-3 in the left ventricular wall. Although the
nﬂuence of blood pressure changes cannot be com-
letely denied, the mechanism by which low-dose
alsartan inhibits cardiac ﬁbrosis seems related to
he induction of apoptosis of ﬁbrotic tissue cells.
We have previously reported that RAAS is
nhanced in SHR given L-NAME [4,6]. Among the
omponents of RAAS in the cardiovascular tissues,
ng II and aldosterone exert various biological





igure 4 Effects of L-NAME and valsartan treatments on mRN
anel). Values in the ordinates are the numbers of mRNA co
p < 0.05, ††p < 0.01 vs. L-NAME.staining in the control (A), L-NAME (B), L-VAL (C), and
hat actions of Ang II are mediated by type 1 and
ype 2 receptors. Stimulation of the Ang II type 1
eceptor activates phospholipase C which generates
nositol triphosphate and diacylglycerol resulting
n the increase of intracellular calcium ion. Well-
nown actions of Ang II such as vasoconstriction
nd aldosterone secretion are mediated by this
athway. The promoter of TGF-1 gene has AP-1
inding site (phorbor ester responsible element),
hich is stimulated with diacyl glycerol in protein
inase C pathway [16—18]. In addition, aldosterone,
ecreted by the stimulation of Ang II, also increases
GF-1 [19]. TGF-1 has biphasic effects on pro-
iferation of mesenchyme type of cells such as
ascular smooth muscle cells and ﬁbroblasts. Low
ose of TGF-1 stimulates but high dose of TGF-1
nhibits proliferation of mesenchyme type of cells.
A expressions of caspase-3 (left panel) and TGF-1 (right
pies per 106 -actin mRNA copies. *p < 0.05 vs. control;
244

























ion percentage of TUNEL-positive nuclei in ﬁbrotic area
of left ventricular tissue. *p < 0.05 vs. control; †p < 0.05,
††p < 0.01 vs. L-NAME.
TGF-1 increases the production of extracellular
matrices and promotes the ﬁbrosis of cardiovascu-
lar and renal tissues [10,11]. Thus, it is considered
that the enhanced RAAS in the cardiovascular
tissues of SHR given L-NAME contributes to the
progression of cardiac ﬁbrosis and the high-dose
valsartan alleviated the cardiac ﬁbrosis by block-






Figure 6 Representative micrographs of TUNEL-staining in
groups.A. Akashiba et al.
As compared with the Ang II type 1 receptor,
ctions of Ang II mediated by the type 2 receptor
ave not been clariﬁed in detail. However, contrary
o the actions of Ang II type 1 receptor, the stim-
lation of type 2 receptor causes vasodilation and
nhibition of proliferation and hypertrophy of car-
iovascular cells. It has been also reported that the
verexpression of Ang II type 2 receptor inhibits the
ype 1 receptor expression by inducing bradykinin
nd NOS in vascular smooth muscle cells [20,21]. In
ddition, the Ang II type 2 receptor has been shown
o elicit apoptosis of cells [22,23]. It is naturally
ssumed that the blocking of Ang II type 1 receptor
y ARB facilitates binding of Ang II to type 2 recep-
ors. In the present study, the cardiac expression
f caspase-3 was increased in rats treated with the
RB, valsartan. Therefore, it is speculated that the
ncreased stimulation of Ang II type 2 receptor by
ype 1 receptor blockade induced apoptosis of car-
iac ﬁbroblasts resulting in the inhibition of cardiac
brosis.
Apoptosis, a morphological form of programmed
ell death, is an indispensable process for the con-
rol of cell populations in various tissues and organs.
t has been indicated that the occurrence of cellu-
ar apoptosis is increased in the injured heart and
s supposed to have a role in the deletion of tissue
olume associated with cardiac remodeling [24,25].
n the healing process after myocardial infarction,
he deletion by apoptosis of damaged and non-
unctioning cardiac cells, inﬁltrating inﬂammatory





























































[alsartan inhibits hypertensive cardiac ﬁbrosis
ells, and ﬁbroblasts is beneﬁcial for the resolution
f infarcted tissue and the reduction of ﬁbrosis [26].
e have previously reported that SHR given L-NAME
evelop coronary arterial injury and myocardial
nfarction and ﬁbrosis [5]. In the present study, val-
artan reduced cardiac ﬁbrosis in SHR given L-NAME
nd the effect may be partly mediated by the stim-
lation of Ang II type 2 receptor resulting in the
nduction of apoptosis in ﬁbrosing tissue cells. Such
eneﬁcial effect of AngII type 2 receptor-mediated
ignal transduction seems to occur when the tis-
ue injuries exist in the heart considering that the
xpression of Ang II type 2 receptor has been shown
o increase in hypertrophied, infarcted, or failing
earts [27,28]. The increases in caspase-3 expres-
ion and apoptotic nuclei did not differ between
he L-VAL and the H-VAL groups. Ang II displaced by
ow-dose valsartan occupies the cardiac Ang II type
receptors; however, the results of this study do
ot substantially provide information as to the lack
f dose-dependency in the induction of ﬁbrocyte
poptosis by valsartan.
The physiological and pathological roles of Ang II
ype 2 receptor have been investigated in exper-
mental studies using the Ang II type 2 receptor
ene knock-out mice. These gene knock-out mice
ave been shown to develop increased perivascular
brosis in response to L-NAME administration and
ggravation of cardiac remodeling after myocar-
ial infarction [29,30]. In addition, it has been also
eported that an ARB failed to bring about attenu-
tion of post-myocardial infarction remodeling and
melioration of heart failure in the Ang II type
receptor gene knock-out mice [31]. These ﬁnd-
ngs are in line with the results of the present
tudy and indicate that the stimulation of Ang II
ype 2 receptor counteracts the development of
ardiac remodeling and thus the cardioprotective
ffects of ARB are partly mediated by this recep-
or.
In conclusion, the ARB valsartan alleviates the
evelopment of cardiac ﬁbrosis in SHR given L-NAME
hich is a model of hypertensive cardiovascu-
ar organ injury. In addition to the hypotensive
ffect, inhibition of TGF-1 expression and induc-
ion of ﬁbrosing tissue cell apoptosis are involved
n this protective effect of valsartan against car-
iac remodeling. The results of the present study
eem to provide information as to the mechanism
f the cardioprotective effects of an ARB.cknowledgments
e thank Ms Y. Mamada, Ms M. Nomura, and Ms N.
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